Caribou Biosciences, Inc. (CRBU)
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Rachel E. Haurwitz Ph.D. | Co-Founder, CEO, President & Director | 832.92k | -- | 1986 |
| Mr. Timothy P. Kelly M.B.A. | Chief Technology Officer | 730.05k | -- | 1969 |
| Dr. Steven B. Kanner Ph.D. | Chief Scientific Officer | 668.62k | -- | 1960 |
| Ms. Barbara G. McClung Esq., J.D. | Chief Legal Officer & Corporate Secretary | 668.62k | -- | 1955 |
| Mr. Sriram Ryali M.B.A. | Chief Financial Officer | -- | -- | 1982 |
| Mr. Daniel Poon | Vice President of Operations & Information Technology | -- | -- | -- |
| Mr. Ryan Fischesser | Interim Principal Accounting Officer & Controller | -- | -- | -- |
| Ms. Amy Figueroa C.F.A. | Vice President of Investor Relations & Corporate Communications | -- | -- | -- |
| Ms. Reigin Zawadzki | Chief People Officer | -- | -- | -- |
| Ms. Ruhi A. Khan M.B.A. | Chief Business Officer | 573.9k | -- | 1975 |
Caribou Biosciences, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 147
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and autoimmune diseases in the United States and internationally. The company's lead product candidate include CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma, refractory systemic lupus erythematosus, lupus nephritis, and extrarenal lupus. It also develops CB-011, an anti-BCMA allogeneic CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Corporate Governance
Upcoming Events
May 8, 2025 at 8:04 PM UTC
Caribou Biosciences, Inc. Earnings Date